ArticleLeukemia2025
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Abstract read
In one paragraph
Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.Blood advances · 2026Review
- Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.Experimental hematology & oncology · 2026Article
- Review
- Pandora's Box of AML: HowBiomedicines · 2025Review
- Molecular and Clinical Insights intoInternational journal of molecular sciences · 2025Review
- Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate.bioRxiv : the preprint server for biology · 2025Article
- Review
- Targeting lipid metabolic vulnerabilities with small-molecule inhibitors in acute myeloid leukemia: Emerging insights and therapeutic opportunities.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Sarah J SkuliDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7711-0732
A'ishah BakayokoDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Marisa KruidenierDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bryan ManningDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Paige PammerDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Akmal SalimovDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0002-0186-3708
Owen RileyDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gisela Brake-SilláDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Derrick DopkinDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael BowmanDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Leslie N Martinez-GutierrezDepartment of Medicine - Leukemia, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Colin C AndersonDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Julie A ReiszDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Roberta BuonoDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA.ORCID 0000-0002-0033-5375
Madhuri PaulDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA.
Estelle SalandCentre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France.
Francesca LiccardoCentre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France.ORCID 0000-0002-6391-9925
Ann DeVineDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sarah WongDepartment of Research and Development, Tevogen Bio, Philadelphia, PA, USA.
Jimmy P XuDepartment of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA.
Eva NeeDepartment of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7838-6586
Ryan HauslerDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Steffen BoettcherDepartment of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Said M SebtiDepartment of Pharmacology and Toxicology and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Catherine LaiDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kara N MaxwellDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8192-4202
Jean-Emmanuel SarryCentre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France.ORCID 0000-0002-6704-2032
David A FrumanDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA.ORCID 0000-0002-1796-5162
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-2258-6490
Clementina MesarosDepartment of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA.
Brian KeithDepartment of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA.
M Celeste SimonAbramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Pamela J SungDepartment of Medicine - Leukemia, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-5828-5622
Gerald WertheimDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicolas SkuliDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Robert L BowmanDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-8294-8748
Andrew MatthewsDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Martin CarrollDivision of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. carroll2@pennmedicine.upenn.edu.ORCID 0000-0002-5622-3735
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6MUniv.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MTranslational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI A. Clementina Mesaros · 2006 to 2026
$35.3MHEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1MInstitutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7MMetabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease ProgressionR35CA220483 · NCI · UNIVERSITY OF PENNSYLVANIA · PI M. CELESTE SIMON · 2017 to 2026
$9.4MTargeting Mutant KRAS for Cancer TherapyR35CA197731 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SEBTI, SAID M · 2016 to 2022
$6.2MUniversity of Pennsylvania Patient-derived Xenograft Development and Trials CenterU54CA283759 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MARTIN CARROLL · 2023 to 2026
$5.1MImproving targeted therapy in FLT3-mutated AMLK08CA230190 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SUNG, PAMELA JEANNETTE · 2020 to 2024
$1.0MInterrogating oncogene-dependency and mutation order in FLT3 mutant AMLR00CA248460 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BOWMAN, ROBERT LYLE · 2022 to 2024
$743kAmerican Society of Clinical Oncology (ASCO) YIAAmerican Society of Hematology (ASH) RTAFBLRD VA I01 BX000918NCATS NIH HHS KL2 TR001879NCI NIH HHS K08 CA230190NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA062203NCI NIH HHS R00 CA248460NCI NIH HHS R35 CA197731NCI NIH HHS R35 CA220483NCI NIH HHS U54 CA283759NHLBI NIH HHS T32 HL007439NIEHS NIH HHS P30 ES013508U.S. Department of Defense (United States Department of Defense) W81XWH-20-1-0867U.S. Department of Health & Human Services | National Institutes of Health (NIH) K08CA230190U.S. Department of Health & Human Services | National Institutes of Health (NIH) KL2TR001879U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30CA046934U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30CA16056U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30ES013508U.S. Department of Health & Human Services | National Institutes of Health (NIH) R00CA248460U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35CA197731U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35CA220483U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32HL0439U.S. Department of Health & Human Services | National Institutes of Health (NIH) U54CA283759U.S. Department of Veterans Affairs (Department of Veterans Affairs) I01BX000918
Abstract
Acute myeloid leukemia with mutations in TP53 (TP53
Indexed as
Drug Resistance, NeoplasmLeukemia, Myeloid, AcuteMevalonic AcidMutationPolyisoprenyl PhosphatesTumor Suppressor Protein p53AnimalsCell Line, TumorCytarabineFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiceMitochondriaReactive Oxygen SpeciesCytarabinegeranylgeranyl pyrophosphateHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidPolyisoprenyl PhosphatesReactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.